As a prototypic inhibitor of the IL-6R signaling pathway, Herzog et al. employed tocilizumab (Genentech), a humanized monoclonal anti-IL-6R antibody that has been approved by the US Food and Drug Administration (FDA) for rheumatoid arthritis since 2010 [112]. Here, IL6R is linked to rheumatoid arthritis.